Stay updated on Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.

Latest updates to the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page
- Check5 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check12 days agoChange DetectedThe site footer revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe study page now displays a 403 Forbidden error page, replacing the previous study content with an access-denied screen. This shows a basic error layout with a 403 message and site footer, indicating restricted access rather than updated study details.SummaryDifference23%

- Check54 days agoChange DetectedThe page's Revision tag was updated from v3.6.5 to v3.6.6, reflecting a new version of the page metadata.SummaryDifference0.0%

- Check76 days agoChange DetectedPlatform revision updated from v3.6.4 to v3.6.5, indicating a minor backend/UI release. No visible changes to the study page content are evident.SummaryDifference0.0%

- Check83 days agoChange DetectedUPMC Hillman Cancer Center was added as a participating site for the study. University of Pittsburgh Cancer Institute (UPCI) was removed.SummaryDifference0.2%

Stay in the know with updates to Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.